Quick Takeaways
- ROCHE FINANCE LTD filed SCHEDULE 13G/A for Entrada Therapeutics, Inc. Common Stock, $0.0001 par value per share (TRDA).
- Disclosed ownership: 6.9%.
- Date of event: 31 Dec 2024.
ROCHE FINANCE LTD - 31 Dec 2024 SCHEDULE 13G/A Report for Entrada Therapeutics, Inc. Common Stock, $0.0001 par value per share (TRDA)
- Filing Manager
- ROCHE FINANCE LTD
- Reporting Manager
- Roche Finance Ltd
- Symbol
- TRDA
- Shares outstanding
- 37,233,551 shares
- Disclosed Ownership
- 2,569,115 shares
- Ownership
- 6.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 15:47:55 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"ROCHE FINANCE LTD disclosed 6.9% ownership in Entrada Therapeutics, Inc. Common Stock, $0.0001 par value per share (TRDA) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 15:47.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Roche Finance Ltd | 6.9% | 2,569,115 | 0 | 2,569,115 | /s/ Carole Nuechterlein | Carole Nuechterlein, Authorized Signatory | |
| Roche Holding Ltd | 6.9% | 2,569,115 | 0 | 2,569,115 | /s/ Peter Trybus | Peter Trybus, Authorized Signatory |